IRVINE - Edwards Lifesciences (NYSE:EW)股价在该医疗设备制造商报告超出分析师预期的第二季度财报后飙升7.6%,这一强劲表现得益于所有产品组的出色业绩。 公司报告调整后每股收益为0.67美元,超过分析师共识的0.62美元,同时收入增长11.9%至15.3亿美元,超过了14.9亿美元的预期。按调整后基准计算,收入较去年同期增长10.6%。 Edwards的经导管...
Source LinkIRVINE - Edwards Lifesciences (NYSE:EW)股价在该医疗设备制造商报告超出分析师预期的第二季度财报后飙升7.6%,这一强劲表现得益于所有产品组的出色业绩。 公司报告调整后每股收益为0.67美元,超过分析师共识的0.62美元,同时收入增长11.9%至15.3亿美元,超过了14.9亿美元的预期。按调整后基准计算,收入较去年同期增长10.6%。 Edwards的经导管...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.